Quick Answer
Ernexa Therapeutics Inc. reported Operating Income of -$9.32 million for fiscal year 2025.
Ernexa Therapeutics Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$9.32M | +40.5% |
| 2024 | -$15.67M | +25.8% |
| 2023 | -$21.14M | +36.4% |
| 2022 | -$33.22M | +70.8% |
| 2021 | -$113.73M | -329.4% |
| 2020 | -$26.49M | -1403.3% |
| 2019 | -$1.76M | -968.0% |
| 2018 | $203.0K | +114.5% |
| 2017 | -$1.40M | +38.5% |
| 2016 | -$2.28M | +67.0% |
| 2015 | -$6.89M | -45.4% |
| 2014 | -$4.74M | -323.8% |
| 2013 | -$1.12M | -5.4% |
| 2012 | -$1.06M | +67.6% |
| 2011 | -$3.28M | -908.0% |
| 2010 | -$325.0K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.99M | +11.8% | +20.3% |
| June 30, 2025 | -$2.50M | +49.3% | +8.4% |
| March 31, 2025 | -$2.73M | +52.8% | -20.8% |
| September 30, 2024 | -$2.26M | +59.0% | +54.2% |
| June 30, 2024 | -$4.93M | -8.4% | +14.8% |
| March 31, 2024 | -$5.79M | -8.9% | -5.1% |
| September 30, 2023 | -$5.50M | +33.7% | -21.0% |
| June 30, 2023 | -$4.55M | +67.2% | +14.4% |
- Ernexa Therapeutics Inc. showed an increase of +40.5% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, Ernexa Therapeutics Inc.’s operating income has declined by 2767.4% (from -$325.0 thousand to -$9.32 million).
- The most recent figure is from Ernexa Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: